Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 07/29 10:00:35 pm
58.66 USD   +0.39%
07/30DJMERCK : Earnings Watch -- WSJ
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29 DOW MOVERS : Xom, mrk
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/21/2012 | 11:46am CEST

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at tapan.panchal@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
07/30DJMERCK : Earnings Watch -- WSJ
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29 DOW MOVERS : Xom, mrk
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
07/29 MERCK & CO., INC. : Results of Operations and Financial Condition, Financial Sta..
07/29 MERCK : European Commission Grants Marketing Authorisation for MSD’s ZEPAT..
07/29 MERCK : beats 2Q profit forecasts
07/29 MERCK : Announces Second-Quarter 2016 Financial Results
07/28 MERCK : Patent Issued for Caspofungin Composition (USPTO 9393307)
More news
Sector news : Pharmaceuticals - NEC
07/30 BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/29 Real Estate Is Bigger Than REITs! Here's More.
07/29 Merck & Co. (MRK) Kenneth C. Frazier on Q2 2016 Results - Earnings Call Trans..
07/29 Big Week Climaxes With A First Look At GDP Along With Pharma, Energy Earnings
07/29 Merck earnings up 75%; Non-GAAP EPS up 8% in Q2; updates guidance
07/29 Merck beats by $0.02, beats on revenue
Advertisement
Financials ($)
Sales 2016 39 496 M
EBIT 2016 13 520 M
Net income 2016 5 867 M
Debt 2016 4 427 M
Yield 2016 3,15%
P/E ratio 2016 27,66
P/E ratio 2017 19,68
EV / Sales 2016 4,22x
EV / Sales 2017 4,20x
Capitalization 162 372 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 62,1 $
Spread / Average Target 5,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.11.06%162 372
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-10.46%218 231
NOVARTIS AG-5.30%215 109
BRISTOL-MYERS SQUIBB C..8.75%124 997
More Results